Reviva Pharmaceuticals Holdings Inc (RVPH)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$0.53-1.85%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · RVPH
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -89.3% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name is a smaller-cap name (higher miss base rate) and has erratic recent earnings surprises. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
RVPH — legal / regulatory event — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standar…
Dated 2026-05-13
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard ; Transfer of Listing. As previously disclosed, the common stock of Reviva Pharmaceuticals Holdings, Inc. (the “Company”) was not in compliance with the requirement under Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”) to maintain a minimum bid price of $1.00 per share for continued listing on The Nasdaq Capital Market (“Nasdaq”) and the Company had until May 11, 2026, which was the maximum extent of t…
Why it matters: Compliance is critical for Reviva's stock to remain listed. It affects investor confidence.
Worry ifA public statement shows compliance with Nasdaq listing rules.
Less concerning ifMore notices about being removed from Nasdaq or not following its rules.
Why it matters: This study is key to confirm the new brilaroxazine formulation is similar. Success could help with approvals.
Supportive ifThe bioequivalence study is done. It shows the new formulation is like the original.
Worry ifThe study does not show the new formulation is similar.
Why it matters: Success shows Reviva can manage trials well. This affects future funding.
Supportive ifGood updates on trial progress and how many patients join.
Worry ifHolds or issues in running trials or finding patients.
Why it matters: Starting this trial is important for Reviva's plan with brilaroxazine. Delays may hurt progress and investor trust.
Supportive ifPatient enrollment in the RECOVER-2 trial begins as planned in the first half of 2027.
Worry ifEnrollment is delayed beyond the first half of 2027 due to financing or other issues.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$453 on $10,000 · ±4.5% | How much price usually moves either way. |
| Bad day | $1,536 loss on $10,000 · 15.4% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,802 loss on $10,000 · 98.0% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: FDA feedback is crucial for Reviva's plans to use a new brilaroxazine form in trials. Positive feedback could support the drug's regulatory path.
Supportive ifFDA gives good feedback on the new brilaroxazine for the RECOVER-2 trial.
Worry ifFDA feedback is bad or shows big concerns about the new formulation.